Wolverine Trading
ALNY icon

Wolverine Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wolverine Trading’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.8M Buy
6,262
+5,140
+458% +$2.09M ﹤0.01% 1879
2025
Q2 		$362K Sell
1,122
-1,316
-54% -$364K ﹤0.01% 3269
2025
Q1 		$655K Sell
2,438
-4,885
-67% -$1.26M ﹤0.01% 2666
2024
Q4 		$1.73M Buy
+7,323
New +$1.93M ﹤0.01% 2092
2024
Q1 		– Sell
-2,946
Closed -$491K – 4415
2023
Q4 		$564K Buy
+2,946
New +$502K ﹤0.01% 2830
2023
Q1 		– Sell
-1,323
Closed -$278K – 4154
2022
Q4 		$314K Buy
+1,323
New +$282K ﹤0.01% 2720
2022
Q3 		– Sell
-2,997
Closed -$572K – 4520
2022
Q2 		$436K Buy
2,997
+1,425
+91% +$202K ﹤0.01% 2676
2022
Q1 		$260K Sell
1,572
-2,054
-57% -$313K ﹤0.01% 4085
2021
Q4 		$620K Buy
3,626
+1,482
+69% +$275K ﹤0.01% 3192
2021
Q3 		$380K Sell
2,144
-4,622
-68% -$867K ﹤0.01% 4351
2021
Q2 		$1.12M Buy
6,766
+2,394
+55% +$351K ﹤0.01% 2631
2021
Q1 		$591K Buy
4,372
+962
+28% +$145K ﹤0.01% 3477
2020
Q4 		$447K Buy
+3,410
New +$455K ﹤0.01% 3294
2020
Q1 		– Sell
-5,440
Closed -$628K – 4551
2019
Q4 		$624K Buy
+5,440
New +$542K ﹤0.01% 2872
2019
Q3 		– Sell
-7,356
Closed -$582K – 4231
2019
Q2 		$534K Buy
+7,356
New +$564K ﹤0.01% 2648
2019
Q1 		– Sell
-13,618
Closed -$1.14M – 4455
2018
Q4 		$959K Sell
13,618
-12,860
-49% -$989K ﹤0.01% 1996
2018
Q3 		$2.32M Buy
+26,478
New +$2.66M 0.01% 1540
2018
Q1 		– Sell
-10,288
Closed -$1.33M – 5068
2017
Q4 		$1.31M Buy
+10,288
New +$1.29M ﹤0.01% 1930
2017
Q1 		– Sell
-9,069
Closed -$340K – 4167
2016
Q4 		$340K Buy
+9,069
New +$380K ﹤0.01% 3109

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Wolverine Trading's ALNY Position: Q3 2025 in Review

Wolverine Trading increased its Alnylam Pharmaceuticals (ALNY) stake by 458% in Q3 2025, buying an estimated $2.09M and bringing the position to 6,262 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1879.

Wolverine Trading first reported a position in ALNY in Q4 2016 and has held it in 19 quarters since. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Wolverine Trading held 6,262 shares of Alnylam Pharmaceuticals worth $2.8M as of Q3 2025.
  • Wolverine Trading bought 5,140 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $2.09M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1879 holding.
  • Wolverine Trading first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.